Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F24%3A00080218" target="_blank" >RIV/65269705:_____/24:00080218 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/24:00136490

Výsledek na webu

<a href="https://ashpublications.org/bloodadvances/article/8/11/2890/515667/Serum-chemistry-profiling-and-prognostication-in" target="_blank" >https://ashpublications.org/bloodadvances/article/8/11/2890/515667/Serum-chemistry-profiling-and-prognostication-in</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1182/bloodadvances.2024012756" target="_blank" >10.1182/bloodadvances.2024012756</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM

Popis výsledku v původním jazyce

Certain laboratory abnormalities correlate with subvariants of systemic mastocytosis (SM) and are often prognostically relevant. To assess the diagnostic and prognostic value of individual serum chemistry parameters in SM, 2607 patients enrolled within the European Competence Network on Mastocytosis and 575 patients enrolled within the German Registry on Eosinophils and Mast Cells were analyzed. For screening and diagnosis of SM, tryptase was identified as the most speci fic serum parameter. For differentiation between indolent and advanced SM (AdvSM), the following serum parameters were most relevant: tryptase, alkaline phosphatase, beta 2-microglobulin, lactate dehydrogenase (LDH), albumin, vitamin B12, and C-reactive protein (P &lt; .001). With regard to subvariants of AdvSM, an elevated LDH of &gt;= 260 U/L was associated with multilineage expansion (leukocytosis, r = 0.37, P &lt; .001; monocytosis, r = 0.26, P &lt; .001) and the presence of an associated myeloid neoplasm (P &lt; .001), whereas tryptase levels were highest in mast cell leukemia (MCL) vs non-MCL (308 mu g/L vs 146 mu g/L, P = .003). Based on multivariable analysis, the hazard-risk weighted assignment of 1 point to LDH (hazard ratio [HR], 2.1; 95% confidence interval [CI], 1.1-4.0; P = .018) and 1.5 points each to beta 2-microglobulin (HR, 2.7; 95% CI, 1.4-5.4; P = .004) and albumin (HR, 3.3; 95% CI, 1.7-6.5; P = .001) delineated a highly predictive 3-tier risk classification system (0 points, 8.1 years vs 1 point, 2.5 years; &gt;= 1.5 points, 1.7 years; P &lt; .001). Moreover, serum chemistry parameters enabled further stratification of patients classified as having an International Prognostic Scoring System for Mastocytosis-AdvSM1/2 risk score (P = .027). In conclusion, serum chemistry pro filing is a crucial tool in the clinical practice supporting diagnosis and prognostication of SM and its subvariants.

Název v anglickém jazyce

Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM

Popis výsledku anglicky

Certain laboratory abnormalities correlate with subvariants of systemic mastocytosis (SM) and are often prognostically relevant. To assess the diagnostic and prognostic value of individual serum chemistry parameters in SM, 2607 patients enrolled within the European Competence Network on Mastocytosis and 575 patients enrolled within the German Registry on Eosinophils and Mast Cells were analyzed. For screening and diagnosis of SM, tryptase was identified as the most speci fic serum parameter. For differentiation between indolent and advanced SM (AdvSM), the following serum parameters were most relevant: tryptase, alkaline phosphatase, beta 2-microglobulin, lactate dehydrogenase (LDH), albumin, vitamin B12, and C-reactive protein (P &lt; .001). With regard to subvariants of AdvSM, an elevated LDH of &gt;= 260 U/L was associated with multilineage expansion (leukocytosis, r = 0.37, P &lt; .001; monocytosis, r = 0.26, P &lt; .001) and the presence of an associated myeloid neoplasm (P &lt; .001), whereas tryptase levels were highest in mast cell leukemia (MCL) vs non-MCL (308 mu g/L vs 146 mu g/L, P = .003). Based on multivariable analysis, the hazard-risk weighted assignment of 1 point to LDH (hazard ratio [HR], 2.1; 95% confidence interval [CI], 1.1-4.0; P = .018) and 1.5 points each to beta 2-microglobulin (HR, 2.7; 95% CI, 1.4-5.4; P = .004) and albumin (HR, 3.3; 95% CI, 1.7-6.5; P = .001) delineated a highly predictive 3-tier risk classification system (0 points, 8.1 years vs 1 point, 2.5 years; &gt;= 1.5 points, 1.7 years; P &lt; .001). Moreover, serum chemistry parameters enabled further stratification of patients classified as having an International Prognostic Scoring System for Mastocytosis-AdvSM1/2 risk score (P = .027). In conclusion, serum chemistry pro filing is a crucial tool in the clinical practice supporting diagnosis and prognostication of SM and its subvariants.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Blood Advances

ISSN

2473-9529

e-ISSN

2473-9537

Svazek periodika

8

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

11

Strana od-do

2890-2900

Kód UT WoS článku

001252795100001

EID výsledku v databázi Scopus

2-s2.0-85196401195